Disease · MONDO_0010150
Comparisons in its trials223
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 223
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Nivolumab + Ipilimumab vs EXTREME Regimen: deaths from any cause | 388 of 472 | 406 of 475 | 947 | NCT02741570 | Trial comparisons |
| Nivolumab + Ipilimumab vs EXTREME Regimen: serious adverse events | 313 of 468 | 290 of 441 | 909 | NCT02741570 | Trial comparisons |
| Pembrolizumab + CRT + Pembrolizumab vs Placebo + CRT + Placebo: deaths from any cause | 156 of 402 | 178 of 402 | 804 | NCT03040999 | Trial comparisons |
| Pembrolizumab + CRT + Pembrolizumab vs Placebo + CRT + Placebo: Number of Participants Who Discontinued Study Drug Due to an AE | 163 of 398 | 132 of 398 | 796 | NCT03040999 | Trial comparisons |
| Pembrolizumab + CRT + Pembrolizumab vs Placebo + CRT + Placebo: Number of Participants Who Experienced an Adverse Event (AE) | 398 of 398 | 397 of 398 | 796 | NCT03040999 | Trial comparisons |
| Pembrolizumab + CRT + Pembrolizumab vs Placebo + CRT + Placebo: serious adverse events | 245 of 398 | 197 of 398 | 796 | NCT03040999 | Trial comparisons |
| Sequence 1: Debio 1143 + CRT vs Sequence 2: Placebo + CRT: deaths from any cause | 111 of 364 | 93 of 366 | 730 | NCT04459715 | Trial comparisons |
| Standard Fractionation RT + Cisplatin vs Accelerated Fractionation RT + Cisplatin: serious adverse events | 293 of 361 | 279 of 360 | 721 | NCT00047008 | Trial comparisons |
| Sequence 1: Debio 1143 + CRT vs Sequence 2: Placebo + CRT: Number of Participants With Severity of Grade Greater or Equal to 3 TEAEs | 320 of 364 | 286 of 356 | 720 | NCT04459715 | Trial comparisons |
| Sequence 1: Debio 1143 + CRT vs Sequence 2: Placebo + CRT: serious adverse events | 194 of 364 | 129 of 356 | 720 | NCT04459715 | Trial comparisons |
| Pembrolizumab + Standard of Care (SOC) vs Standard of Care (SOC): deaths from any cause | 113 of 363 | 131 of 351 | 714 | NCT03765918 | Trial comparisons |
| Avelumab + Standard of Care Chemotherapy (SOC CRT) vs Placebo + SOC CRT: deaths from any cause | 86 of 348 | 62 of 344 | 692 | NCT02952586 | Trial comparisons |
| Avelumab + Standard of Care Chemotherapy (SOC CRT) vs Placebo + SOC CRT: serious adverse events | 184 of 348 | 177 of 344 | 692 | NCT02952586 | Trial comparisons |
| Lapatinib 1500 mg vs Placebo: Number of Participants With a Second Primary Tumor | 9 of 346 | 5 of 342 | 688 | NCT00424255 | Trial comparisons |
| Lapatinib 1500 mg vs Placebo: serious adverse events | 169 of 349 | 133 of 336 | 685 | NCT00424255 | Trial comparisons |
| Pembrolizumab + Standard of Care (SOC) vs Standard of Care (SOC): serious adverse events | 179 of 361 | 116 of 315 | 676 | NCT03765918 | Trial comparisons |
| Panitumumab Plus Chemotherapy vs Chemotherapy Alone: serious adverse events | 157 of 325 | 139 of 325 | 650 | NCT00460265 | Trial comparisons |
| Afatinib (BIBW 2992) vs Placebo: serious adverse events | 80 of 411 | 51 of 206 | 617 | NCT01345669 | Trial comparisons |
| IMRT vs IMRT Plus Cetuximab: deaths from any cause | 97 of 287 | 87 of 290 | 577 | NCT00956007 | Trial comparisons |
| IMRT vs IMRT Plus Cetuximab: serious adverse events | 50 of 282 | 83 of 276 | 558 | NCT00956007 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0010150/comparisons